The Human Nuclear Co-Repressor Gene: Applications for Cancer Diagnostics/Therapeutics and Gene Expression Research
Posted Jul 20 2011 8:00pm
Description of Invention: The human nuclear receptor co-repressor (huN-CoR) forms multimolecular complexes that alters chromatin structure, resulting in disrupted gene expression. The huN-CoR complex is central to normal processes such as erythropoiesis and thymocyte development, but is also linked to multiple cancers including colorectal carcinomas, endometrial cancers and leukemia, particularly acute myeloid leukemia. Thus, huN-CoR is a potentially-valuable tool for cancer diagnosis, as well as a target for the development of huN-CoR-based cancer therapeutics. HuN-CoR is also an attractive research tool for the study of gene regulation, epigenetic modification and gene silencing.
The technology claims nucleic acid sequences comprising the huN-CoR gene and fragments thereof, as well as a gene chip array incorporating such fragments.
Applications:
Target for novel anti-cancer therapies
Use as a tool for prognosis and diagnosis of HuN-Cor-related diseases
Use as a target for antibody production and development of biological assays to diagnose human disease related to HuN-CoR
Target for rational drug design of novel agents to reverse transcriptional repression
Study of molecular repression of targeted genes using HuN-Cor fusion proteins
Inventors: Johnson M Liu (NHLBI) Jianxiang Wang (NHLBI)
Wang J, Wang M, Liu JM. Domains involved in ETO and human N-CoR interaction and ETO transcription repression. Leuk Res. 2004 Apr;28(4):409-414. [ PMID: 15109542 ]
Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10860-10865. [ PMID: 9724795 ]
Licensing Status: Available for licensing.
For Licensing Information Please Contact: Tara Kirby Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: tk200h@nih.gov Phone: 301-435-4426 Fax: 301-402-0220
Description of Invention:
The human nuclear receptor co-repressor (huN-CoR) forms multimolecular complexes that alters chromatin structure, resulting in disrupted gene expression. The huN-CoR complex is central to normal processes such as erythropoiesis and thymocyte development, but is also linked to multiple cancers including colorectal carcinomas, endometrial cancers and leukemia, particularly acute myeloid leukemia. Thus, huN-CoR is a potentially-valuable tool for cancer diagnosis, as well as a target for the development of huN-CoR-based cancer therapeutics. HuN-CoR is also an attractive research tool for the study of gene regulation, epigenetic modification and gene silencing.
The technology claims nucleic acid sequences comprising the huN-CoR gene and fragments thereof, as well as a gene chip array incorporating such fragments.
Applications:
Inventors:
Johnson M Liu (NHLBI)
Jianxiang Wang (NHLBI)
Patent Status:
HHS, Reference No. E-088-1999/0
US, , Patent No. 6,949,624, Issued 27 Sep 2005
Relevant Publication:
Licensing Status:
Available for licensing.
For Licensing Information Please Contact:
Tara Kirby Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: tk200h@nih.gov
Phone: 301-435-4426
Fax: 301-402-0220
Ref No: 461
Updated: 07/2011